GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » 3-Year FCF Growth Rate

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) 3-Year FCF Growth Rate : 37.00% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group 3-Year FCF Growth Rate?

Sihuan Pharmaceutical Holdings Group's Free Cash Flow per Share for the six months ended in Dec. 2023 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 37.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sihuan Pharmaceutical Holdings Group was 128.90% per year. The lowest was -20.80% per year. And the median was 28.75% per year.


Competitive Comparison of Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate falls into.



Sihuan Pharmaceutical Holdings Group 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Sihuan Pharmaceutical Holdings Group 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.